Journal of Endocrinological Investigation

, Volume 21, Issue 4, pp 234–238 | Cite as

The changes of the thyroid function and serum testosterone levels after long-term L-NAME treatment in male rats

  • M. Haluzík
  • J. Nedvídková
  • V. Kopský
  • J. Jahodová
  • B. Hořejší
  • V. Schreiber
Article

Abstract

Nitric oxide is a highly reactive gas that is produced by many tissues and exerts a series of physiological and pathophysiological effects. We studied the changes of the serum testosterone, thyroxine and thyrotropin levels, thyroid and anterior pituitary weights and thyroid cGMP concentrations in male Wistar strain rats treated with estradiol benzoate (EB) (1 mg/kg, im twice a week) and nonselective NO-synthase inhibitor L-NAME (N-omega-nitro-L-arginine methyl ester) alone and with combination of these substances. We have found that L-NAME in a dose 100 mg/kg/day but not in a dose 50 mg/kg/day increased the serum thyroxine and testosterone levels and in the case of testosterone in a higher dose partially blocked its drop when administered simultaneously with EB. The serum thyrotropin levels significantly fell after L-NAME and EB treatment. The cGMP thyroid levels changed only slightly in groups treated EB and L-NAME alone and were significantly decreased in group treated with combination of these substances. The nitric oxide thus seems to be an important modulator of thyroid and testicular function. The cGMP activation cascade is not probably involved in the nitric oxide induced changes of thyroid function.

Key-words

L-NAME nitric oxide thyroid thyroxine TSH testosterone estradiol benzoate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Palmer R.M.J., Ferrige A.G., Moncada S. Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 88: 411, 1987.Google Scholar
  2. 2.
    Paya D., Gray G.A., Stoclet J. C. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J. Card. Pharm. 21: 926, 1993.CrossRefGoogle Scholar
  3. 3.
    Midgley S., Grant I.S., Haynes W.G., Webb D.J. Nitric oxide in liver failure. Lancet II: 1590, 1990.Google Scholar
  4. 4.
    Colin I.M., Nava E., Toussaint D., Maiter D.M., VanDenhove M.F., Luscher T.F., Ketelslegers J.M., Denef J.F., Jameson J.L. Expression of nitric oxide synthase isoforms in the thyroid gland: evidence for a role of nitric oxide in vascular control during goiter formation. Endocrinology 136: 5283, 1995.PubMedGoogle Scholar
  5. 5.
    Motohashi S., Kasai K., Banba N., Hattori Y., Shimoda S. Nitric oxide inhibits cell growth in cultured human thyrocytes. Life Sci. 59: 227, 1996.CrossRefGoogle Scholar
  6. 6.
    Kasai K., Hattori Y., Nakanishi N., Manaka K., Banba N., Motohashi S., Shimoda S. Regulation of inducible nitric oxide production by cytokines in human thyrocytes in culture. Endocrinology 136: 4261, 1995.PubMedGoogle Scholar
  7. 7.
    López-Moratalla N., Calleja A., González A., Pérez-Mediavilla L.A., Aymench M.S., Burrel M.A., Santiago I.E. Inducible nitric oxide synthase in monocytes from patients with Graves disease. Biochem. Biophys. Res. Commun. 226: 723, 1996.PubMedCrossRefGoogle Scholar
  8. 8.
    Mayer B., Brunner F., Schmidt K. Novel actions of methylene blue. Eur. Heart J. 14 Suppl.: 122, 1993.CrossRefGoogle Scholar
  9. 9.
    Nedvídková J., Šterzi I., Haluzik M., Schreiber V. An increase in the blood thyroxine level after methylene blue in rats: the interaction with carbimazole. Endocr. Res. 21: 709, 1995.PubMedCrossRefGoogle Scholar
  10. 10.
    Haluzik M. Methylene blue — the new effects of an old drug. The thyroid gland, clinical and experimental. 1: 7, 1997.Google Scholar
  11. 11.
    Schreiber V., Nedvídková J., Jahodová J. Anterior pituitary weight, cAMP, cGMP and prolactin levels after combined treatment with estradiol and methylene blue. Physiol. Res. 42; 171, 1993.Google Scholar
  12. 12.
    Haluzik M., Nedvídková J., Schreiber V. Adenohypophyseal ascorbic acid: influences of oestradiol and methylene blue. Phys. Res. 44: 333, 1995.Google Scholar
  13. 13.
    Haluzik M., Nedvídková J., Schreiber V. Methylene blue–an endocrine modulator. Sbornik lék. 96: 319, 1995.Google Scholar
  14. 14.
    Snyder S.H. Nitric oxide: first in a new class of neurotransmitters? Science 54: 171, 1992.Google Scholar
  15. 15.
    Desai K.M., Sessa W.C., Vane J.R. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 351: 477, 1991.PubMedCrossRefGoogle Scholar
  16. 16.
    Burnett A.L., Lowenstein C.J., Bredt D.S., Chang T.S.K., Snyder S.H. Nitric oxide: a physiological mediator of penile erection. Science 257: 401, 1992.PubMedCrossRefGoogle Scholar
  17. 17.
    Corbett J.A., Mikhael A., Shimizu J., Frederick K., Misko T.P., McDaniel M.L., Kanagawa O. Nitric oxide production in islets from non obese diabetic mice: aminoguanidine-sensitive and resistant stages in the immunological diabetic process. Proc. Natl. Acad. Sci. USA 90: 8992, 1993.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Adams M.L., Meyer E.R., Sewing B.N., Cicero T.J. Effects of nitric oxide — related agents on rat testicular function. J. Pharmacol. Exp. Ther. 269: 230, 1994.PubMedGoogle Scholar
  19. 19.
    Millatt L.J., Jackson R., Williams B.C., Whitley G.S. Nitric oxide stimulates-cyclic GMP in human thymocytes. J. Mol. Endocrinol. 10: 163, 1993.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1998

Authors and Affiliations

  • M. Haluzík
    • 1
  • J. Nedvídková
    • 2
  • V. Kopský
    • 2
  • J. Jahodová
    • 1
  • B. Hořejší
    • 1
  • V. Schreiber
    • 1
  1. 1.III Department of Internal Medicine, 1∘ Faculty of MedicineCharles UniversityPragueCzech Republic
  2. 2.Institute of EndocrinologyPragueCzech Republic

Personalised recommendations